Results 71 to 80 of about 14,011 (208)

Amodiaquine resistance in Plasmodium berghei is associated with PbCRT His95Pro mutation, loss of chloroquine, artemisinin and primaquine sensitivity, and high transcript levels of key transporters [version 2; referees: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2018
Background: The human malaria parasite Plasmodium falciparum has evolved drug evasion mechanisms to all available antimalarials. The combination of amodiaquine-artesunate is among the drug of choice for treatment of uncomplicated malaria.
Loise Ndung'u, Benard Langat, Esther Magiri, Joseph Ng'ang'a, Beatrice Irungu, Alexis Nzila, Daniel Kiboi   +6 more
doaj   +1 more source

Ein neuer Malariawirkstoff hemmt die Proteinsynthese von Plasmodium falciparum

Angewandte Chemie, Volume 137, Issue 49, December 1, 2025.
Die Verbindung 31 stellt einen vielversprechenden Ansatz für die Entwicklung eines Malariawirkstoffs mit einem starken Wirkungsprofil dar (PfNF54 IC50 ± s.d. = 3,9 ± 0,4 nM). Sie hat einen neuartigen Wirkmechanismus, indem sie an zytosolische Ribosomen‐Untereinheiten bindet und dadurch die Proteinsynthese im Parasiten hemmt.
Patricia Bravo, Eleonora Diamanti, Mostafa M. Hamed, Lorenzo Bizzarri, Natalie Wiedemar, Armin Passecker, Nicolas M. B. Brancucci, Anna Albisetti, Christin Gumpp, Boris Illarionov, Markus Fischer, Matthias Witschel, Tobias Schehl, Hannes Hahne, Pascal Mäser, Matthias Rottmann, Anna K. H. Hirsch   +16 more
wiley   +1 more source

Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali [PDF]

, 2009
Background Because of the emergence of chloroquine resistance in Mali, artemether-lumefantrine (AL) or artesunate-amodiaquine (AS+AQ) are recommended as first-line therapy for uncomplicated malaria, but have not been available in Mali until recently ...
Kassoum Kayentao, Hamma Maiga, Robert D Newman, Meredith L McMorrow, Annett Hoppe, Oumar Yattara, Hamidou Traore, Younoussou Kone, Etienne A Guirou, Renion Saye, Boubacar Traore, Abdoulaye Djimde, Ogobara K Doumbo, H Sangho, X De Radigues, World Health Organization and UNICEF, AA Djimdé, I Sagara, CO Obonyo, BJ Bell, MA Thera, K Kayentao, B Faye, FP Mockenhaupt, D Menard, World Health Organization, DA Diallo, N Bakyaita, SG Staedke, CE Rwagacondo, S Krishna, A Yeka   +31 more
core   +2 more sources

A Novel Antimalarial Agent that Inhibits Protein Synthesis in Plasmodium falciparum

Angewandte Chemie International Edition, Volume 64, Issue 49, December 1, 2025.
Compound 31 represents a promising avenue for the development as an antimalarial agent with a potent activity profile (PfNF54 IC50 ± s.d. = 3.9 ± 0.4 nM). It has a novel mode of action by binding to cytosolic ribosomal subunits, thereby inhibiting protein synthesis in the parasite.
Patricia Bravo, Eleonora Diamanti, Mostafa M. Hamed, Lorenzo Bizzarri, Natalie Wiedemar, Armin Passecker, Nicolas M. B. Brancucci, Anna Albisetti, Christin Gumpp, Boris Illarionov, Markus Fischer, Matthias Witschel, Tobias Schehl, Hannes Hahne, Pascal Mäser, Matthias Rottmann, Anna K. H. Hirsch   +16 more
wiley   +1 more source

Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the PfCRT SVMNT type

Malaria Journal, 2010
The loss of chloroquine due to selection and spread of drug resistant Plasmodium falciparum parasites has greatly impacted malaria control, especially in highly endemic areas of Africa.
Twu Olivia, Sa Juliana M
doaj   +1 more source

Amodiaquine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine [PDF]

, 2014
Amodiaquine is an antimalarial drug used in the prophylaxis and treatment of this disease. However, hepatotoxicity as a life-threatening adverse effect is associated with its clinical use.
Babaei, H., Eghbal, M.A., Heidari, R.
core   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali

Malaria Journal, 2009
Background To update the National Malaria Control Programme of Mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria.
Wele Mamadou, Dembele Demba, Kone Aminatou, Dama Souleymane, Ouologuem Dinkorma, Fofana Bakary, Sagara Issaka, Maiga Hamma, Beavogui Abdoul H, Djimde Abdoulaye A, Tekete Mamadou, Dicko Alassane, Doumbo Ogobara K   +12 more
doaj   +1 more source

Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change

The Pan African Medical Journal, 2020
INTRODUCTION: Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso. We assessed the treatment efficacy, tolerability of these drugs 11 years following its adoption as first ...
Issaka Zongo, Yves Daniel Compaoré, Frédéric Nikiéma, Moussa Zongo, Nouhoun Barry, Fabrice Anyirékun Somé, Naomie Kaboré, Jean Bosco Ouédraogo   +7 more
doaj   +1 more source

Amodiaquine

, 2006
europepmc   +2 more sources